La vendita allo scoperto per Syndax Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Syndax Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Syndax Pharmaceuticals (NASDAQ:SNDX) Azioni, Report sulle vendite allo scoperto

SYNDAX PHARMACEUTICALS INC

Syndax Pharmaceuticals

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial –
– Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate –
– sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 –
NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been <a href="https://www.globenewswire.com/Tracker?data=HgKy5C2YZkNevu3gvMKYfT9ddafykYDpCX9nwMwmfCE52FG-kbtj3b2qYfKbkQLUG9XZJAGU6wnWCP5L04VKOPOm0OV5rWzQrIRHJ4Z21lGDVI0tIrpWCsYoyn3Dc919DUnel0CkQovP3-3HDaUq3klmCmvgvQRHUupU6k1V9ytWmTR2BljkBdu_nFNkYlhoxpUQcbpDqsqwMl30wAvSMGlSReLemkyMzwCRK3NzSV4=">published</a> in Blood.

News

SNDX

Syndax Pharma Publishes Data From Pivotal Phase 2 Portion Of AUGMENT-101 Trial Of Revumenib In Patients With R/R mNPM1 Acute Myeloid Leukemia In Blood

<h3>Gainers</h3>
<ul>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares rose 125.8% to $209.7 during Tuesday's regular session. The market value of their outstanding shares is at $2.7 billion. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 32.66% to $1.87. The company's market cap stands at $25.7 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) shares moved upwards by 28.27% to $1.56. The company's market cap stands at $182.8 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) stock moved upwards by 26.68% to $2.22. The company's market cap stands at $93.8 million. The company's, Q1 earnings came out today. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock moved upwards by 20.02% to $0.36. The market value of their outstanding shares is at $4.9 million. </li>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock increased by 18.37% to $0.76. The market value of their outstanding shares is at $2.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock declined by 67.2% to $0.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 44.74% to $0.21. The company's market cap stands at $3.8 million. </li>
<li>Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) stock decreased by 31.53% to $9.54. The company's market cap stands at $225.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Kodiak Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) shares fell 21.24% to $3.88. The company's market cap stands at $204.4 million. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) shares declined by 21.15% to $10.7. The company's market cap stands at $913.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>HealthStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) shares fell 18.75% to $27.01. The company's market cap stands at $824.4 million. As per the press release, Q1 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BIAF

CCLD

CYCC

HSTM

NCNA

SXTC

TCMD

TLSA

12 Health Care Stocks Moving In Tuesday's Intraday Session

Scotiabank analyst George Farmer maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Sector Perform and raises the price target from $16 to $17.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Raises Price Target to $17

Guggenheim analyst Michael Schmidt reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $32 price target.

Reiteration

Guggenheim Reiterates Buy on Syndax Pharmaceuticals, Maintains $32 Price Target

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.03) by 4.85 percent. This is a 15.29 percent decrease over losses of $(0.85) per share from the same period last year. The company reported quarterly sales of $20.04 million which beat the analyst consensus estimate of $14.43 million by 38.86 percent.

Earnings

Earnings Beats

Syndax Pharmaceuticals Q1 EPS $(0.98) Beats $(1.03) Estimate, Sales $20.04M Beat $14.43M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCRX

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

IART

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NSSC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Tuesday.
Shares of NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) fell sharply in today's pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its <a href="https://in.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">midpoint below estimates</a>.
NXP reported first-quarter revenue of $2.84 billion, in line with analyst estimates, according to Benzinga Pro. The company reported first-quarter adjusted earnings of $2.64 per share, beating analyst estimates of $2.58 per share.
NXP expects second-quarter revenue of $2.8 billion to $3 billion versus estimates of $2.87 billion. The company sees second-quarter adjusted earnings in the range of $2.46 to $2.86 per share versus estimates of $2.65 per share. The company announced CEO Kurt Sievers will retire at the end of 2025.
NXP Semiconductors shares dipped 7.7% to $181.18 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) fell 10.3% to $20.00 in pre-market trading after the company reported worse-than-expected first-quarter financial result and issued second-quarter guidance below estimates.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) declined 9.5% to $9.02 in pre-market trading.</li>
<li>Brinker International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) dipped 8.6% to $146.90 in pre-market trading following third-quarter results.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) fell 8.5% to $547.00 in pre-market trading after the company reported worse-than-expected quarterly earnings.</li>
<li>Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) fell 7.5% to $12.42 in pre-market trading. Syndax Pharmaceuticals will report its first quarter financial results and provide a business update on Monday, May 5.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) fell 7% to $568.00 in pre-market trading following weak quarterly earnings.</li>
<li>Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) fell 5.8% to $76.00 in today's pre-market trading. Sanmina posted upbeat results for its second quarter, but issued weak forecast for the third quarter. The company said it sees third-quarter adjusted earnings of $1.35 to $1.45 per share, versus market estimates of $1.53 per share. It also expects sales of $1.925 billion to $2.025 billion for the current quarter, versus market projections of $2.06 billion.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 4.7% to $18.99 in pre-market trading.</li>
<li>BP p.l.c. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) declined 4.3% to $27.87 in pre-market trading following first-quarter earnings.</li>
<li>AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell 2.8% to $67.96 in pre-market trading following quarterly results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45060164/general-motors-coca-cola-and-3-stocks-to-watch-heading-into-tuesday">General Motors, Coca-Cola And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

HOPE

NXPI

REGN

SANM

SPOT

UCTT

XPEV

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Shares of Leggett &amp; Platt, Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) rose sharply in pre-market trading after the company reported better-than-expected first-quarter EPS results and <a href="https://www.benzinga.com/quote/LEG/earnings">raised its FY25 EPS guidance</a>.
Leggett &amp; Platt reported quarterly earnings of 24 cents per share which beat the analyst consensus estimate of 22 cents per share. The company reported quarterly sales of $1.02 billion which met the analyst consensus estimate.
Leggett &amp; Platt shares jumped 14.8% to $8.35 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Wearable Devices Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDS#NASDAQ">WLDS</a>) rose 55% to $1.86 in pre-market trading after dipping around 25% on Monday.</li>
<li>LogicMark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) surged 46.5% to $0.0189 in pre-market trading after jumping 48% on Monday.</li>
<li>Bon Natural Life Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) surged 43.2% to $0.0931 in pre-market trading after gaining 13% on Monday. Bon Natural Life recently announced it won a $12 million 24-month supply agreement to develop apple polyphenol-infused health solutions.</li>
<li>Tevogen Bio Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) gained 29.1% to $1.21 in pre-market trading after the company reaffirmed its oncology pipeline revenue forecast, projecting $1 billion in its launch year and a cumulative five-year estimate of $10 billion to $14 billion.</li>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) gained 28.6% to $0.1724 in pre-market trading after jumping 175% on Monday.</li>
<li>Odyssey Marine Exploration, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) jumped 17.4% to $1.55 in pre-market trading after dipping over 12% on Monday.</li>
<li>Algoma Steel Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) gained 15.5% to $5.90 in pre-market trading ahead of quarterly earnings.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) gained 14.1% to $4.71 in pre-market trading after jumping 26% on Monday.</li>
<li>Evolv Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) rose 12.3% to $4.67 in pre-market trading following better-than-expected quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Incannex Healthcare Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) shares fell 65.8% to $0.2086 in pre-market trading after declining around 3% on Monday.</li>
<li>First Commonwealth Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCF#NYSE">FCF</a>) shares dipped 21.5% to $12.01 in pre-market trading ahead of quarterly earnings.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) shares fell 21.3% to $5.00 in pre-market trading.</li>
<li>Intelligent Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTJ#NASDAQ">INTJ</a>) fell 14.1% to $0.5792 in pre-market trading after dipping 12% on Monday.</li>
<li>PTL Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTLE#NASDAQ">PTLE</a>) shares tumbled 14% to $1.17 in pre-market trading after gaining around 9% on Monday.</li>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) fell 10.3% to $20.00 in pre-market trading after the company reported worse-than-expected first-quarter financial result and issued second-quarter guidance below estimates.</li>
<li>Hope Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) declined 9.5% to $9.02 in pre-market trading.</li>
<li>NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) dipped 7.7% to $181.18 in pre-market trading after the company reported first-quarter financial results and issued second-quarter EPS guidance with its midpoint below estimates. The company announced CEO Kurt Sievers will retire at the end of 2025.</li>
<li>Syndax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) fell 7.5% to $12.42 in pre-market trading. Syndax Pharmaceuticals will report its first quarter financial results and provide a business update on Monday, May 5.</li>
<li>Sanmina Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) fell 5.8% to $76.00 in today's pre-market trading. Sanmina posted upbeat results for its second quarter, but issued weak forecast for the third quarter. The company said it sees third-quarter adjusted earnings of $1.35 to $1.45 per share, versus market estimates of $1.53 per share. It also expects sales of $1.925 billion to $2.025 billion for the current quarter, versus market projections of $2.06 billion.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45038052/top-2-industrials-stocks-that-may-fall-off-a-cliff-this-quarter">Top 2 Industrials Stocks That May Fall Off A Cliff This Quarter</a> </li>
</ul>
Photo via Shutterstock

AGMH

ASTL

EVLV

INTJ

IXHL

LGMK

NESR

OMEX

PTLE

TVGN

WLDS

WOLF

Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

JP Morgan released a survey on Thursday focused on the launch prospects of Syndax Pharmaceuticals Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) Revuforj (revumenib) in relapsed/refractory (r/r) KMT2A acute leukemias and nucleophosmin 1 mutation acute <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">myeloid leukemia (NPM1 AML)</a>.
The FDA approved Revuforj in November 2024 as the first and only menin inhibitor for r/r acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42020752/syndax-announces-fda-approval-of-revuforj-revumenib-the-first-and-only-menin-inhibitor-to-treat-ad" rel="noreferrer noopener">one year and older</a>.
Revuforj generated $7.7 million in net product revenue during its first five weeks on the market.
The company expects to submit a supplemental application filing for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44073341/syndax-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">around year-end 2025</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40396645/fda-approves-incytesyndax-partnered-drug-for-chronic-graft-versus-host-disease-a-post-transplant-" rel="noreferrer noopener">FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication</a>
JPMorgan says that, on average, surveyed physicians treated 8 KMT2A acute leukemia and 12 NPM1 AML patients.
Overall, surveyed physicians provided high ratings related to Revuforj&#8217;s clinical profile in both r/r KMT2A acute leukemias and NPM1 AML.
Analyst Anupam Rama writes that surveyed physicians indicated a high degree of comfort using Revuforj in r/r NPM1 should the product be incorporated into NCCN guidelines.
&#8220;In our view, survey results underscore that SNDX shares are currently materially undervalued on Revuforj in the r/r (KMT2A / NPM1) setting alone – which we value in the ~high-$20 to low-$30s / share range,&#8221; Rama writes.
For the near term, JPMorgan estimates 2025 Revuforj sales to be around $50 million (US only), largely driven by the KMT2A setting.
JPMorgan raised its price target from $39 to $41, accounting for a faster ramp to peak for Revuforj in both KMT2A acute leukemias and NPM1 AML, reiterating the Overweight rating.
Price Action: SNDX stock is up 0.43% at $14.16 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44432877/asia-markets-mixed-with-weak-china-europe-drops-dollar-strengthens-oil-slips-global-markets-today-while-us-slept" target="_blank" rel="noreferrer noopener">China, Hong Kong, And Europe Markets Dip; Dollar Strengthens &#8211; Global Markets Today While US Slept</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

General

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth

WIIM

Syndax Pharmaceuticals shares are trading higher after JP Morgan raised its price target on the stock from $39 to $41 and maintained an Overweight rating.

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $39 to $41.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $41

JP Morgan analyst Anupam Rama maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Overweight and raises the price target from $35 to $39.

JP Morgan Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and lowers the price target from $45 to $42.

Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $42

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Syndax Pharmaceuticals shares are trading lower after the company reported Q4 financial results and missed its EPS and sales estimate.

For the first quarter of 2025, the Company expects research and development expenses to be&nbsp;$65 to $70 million&nbsp;and total research and development plus selling, general and administrative expenses to be&nbsp;$105 to $110 million. For the full year of 2025, the Company expects research and development expenses to be&nbsp;$260 to $280 million&nbsp;and total research and development plus selling, general and administrative expenses to be&nbsp;$415 to $435 million, which includes an estimated&nbsp;$45 million&nbsp;in non-cash stock compensation expense. The Company is not providing revenue guidance at this time.

Guidance

Syndax Sees Research & Development Expenses Of $65M-$70M In Q1, $260M-$280M In 2025

Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.01) by 8.91 percent. This is a 10 percent decrease over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $7.68 million which missed the analyst consensus estimate of $85.91 million by 91.06 percent.

Earnings Misses

Syndax Pharmaceuticals Q4 2024 GAAP EPS $(1.10) Misses $(1.01) Estimate, Sales $7.68M Miss $85.91M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Sphere Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHR#NYSE">SPHR</a>) is expected to report earnings for its second quarter. 
• TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $99.36 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $274.06 million. 
• Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $216.00 million. 
• Avadel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDL#NASDAQ">AVDL</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $52.70 million. 
• Mersana Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRSN#NASDAQ">MRSN</a>) is projected to report quarterly loss at $0.16 per share on revenue of $7.64 million. 
• AG Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $17.01 million. 
• Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) is likely to report quarterly loss at $1.07 per share on revenue of $21.98 million. 
• Nomad Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOMD#NYSE">NOMD</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $796.56 million. 
• Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) is projected to report quarterly loss at $0.22 per share on revenue of $16.89 million. 
• BioLife Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLFS#NASDAQ">BLFS</a>) is expected to report quarterly loss at $0.03 per share on revenue of $22.77 million. 
• Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) is projected to report quarterly earnings at $0.49 per share on revenue of $828.01 million. 
• N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $113.77 million. 
• Ready Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RC#NYSE">RC</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $55.44 million. 
• Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) is likely to report quarterly loss at $0.35 per share on revenue of $25.62 million. 
• Stereotaxis (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/STXS#AMEX">STXS</a>) is expected to report quarterly loss at $0.06 per share on revenue of $6.42 million. 
• Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) is likely to report quarterly loss at $0.67 per share on revenue of $234.99 million. 
• GEO Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) is likely to report earnings for its fourth quarter. 
• Fortrea Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTRE#NASDAQ">FTRE</a>) is likely to report quarterly earnings at $0.37 per share on revenue of $703.90 million. 
• California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $904.91 million. 
<h3>Companies Reporting After The Bell</h3>
• NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $1.07 million. 
• B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) is likely to report earnings for its fourth quarter. 
• ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>) is projected to report quarterly earnings at $0.16 per share on revenue of $113.40 million. 
• Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) is expected to report quarterly loss at $0.08 per share on revenue of $5.30 million. 
• GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $288.33 million. 
• Smart Sand (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SND#NASDAQ">SND</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $65.90 million. 
• OFS Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFS#NASDAQ">OFS</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $10.30 million. 
• Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) is likely to report earnings for its fourth quarter. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is estimated to report quarterly earnings at $0.23 per share on revenue of $334.82 million. 
• MRC Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRC#NYSE">MRC</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $726.90 million. 
• W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly loss at $0.25 per share on revenue of $130.04 million. 
• Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is estimated to report quarterly earnings at $1.08 per share on revenue of $95.23 million. 
• AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) is expected to report quarterly loss at $0.15 per share on revenue of $1.88 million. 
• Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $142.60 million. 
• James River Gr Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JRVR#NASDAQ">JRVR</a>) is projected to report quarterly loss at $0.46 per share on revenue of $159.91 million. 
• Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is likely to report quarterly loss at $0.08 per share on revenue of $270.50 million. 
• Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $82.56 million. 
• Viant Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSP#NASDAQ">DSP</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $83.91 million. 
• GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) is expected to report quarterly earnings at $0.23 per share on revenue of $206.48 million. 
• Crawford &amp; Company Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRD#NYSE">CRD</a>) is projected to report quarterly earnings at $0.24 per share on revenue of $334.82 million. 
• Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) is expected to report quarterly loss at $0.06 per share on revenue of $19.83 million. 
• Intrepid Potash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPI#NYSE">IPI</a>) is likely to report quarterly loss at $0.05 per share on revenue of $53.44 million. 
• Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) is projected to report quarterly loss at $0.03 per share on revenue of $7.79 million. 
• Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $1.29 million. 
• NCR Atleos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) is estimated to report quarterly earnings at $1.02 per share on revenue of $1.10 billion. 
• Heidrick &amp; Struggles Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSII#NASDAQ">HSII</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $263.33 million. 
• Concentra Group Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $463.65 million. 
• ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $70.65 million. 
• Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $669.10 million. 
• Kayne Anderson BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBDC#NYSE">KBDC</a>) is estimated to report earnings for its fourth quarter. 
• BRC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) is expected to report quarterly loss at $0.05 per share on revenue of $106.20 million. 
• Whitestone REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSR#NYSE">WSR</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $38.39 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADMA

ASTS

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

BDSX

BLFS

DAVE

FTRE

GTLB

GUTS

KBDC

MITT

MRSN

NABL

NATL

NOMD

NOVA

OKTA

PLUG

RILY

RNGR

RPAY

SENS

SGRY

SPHR

STXS

TDUP

TGTX

Earnings Scheduled For March 3, 2025

The Companies expect product to be available for order in the U.S. in early February. Niktimvo is approved for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg (88.2 lbs).
&nbsp;Niktimvo is the first and only FDA-approved prescription treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis.

INCY

Incyte, Syndax Announce FDA Approval Of Niktimvo 9 mg And 22 mg Vial Sizes; US Launch Expected In Early February

Scotiabank analyst George Farmer maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Sector Perform and lowers the price target from $18 to $16.

Scotiabank Maintains Sector Perform on Syndax Pharmaceuticals, Lowers Price Target to $16

Press Releases

Syndax Announces Participation in March Investor Conferences

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

Comments

Syndax Pharmaceuticals

Vendite allo scoperto

Syndax Pharmaceuticals (NASDAQ:SNDX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO